$43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World

December 13, 2004

San Francisco, Calif. - A $42.6 million grant from the Bill & Melinda Gates Foundation to the Institute for OneWorld Health, the first nonprofit pharmaceutical company in the United States, will create a powerful new approach to developing a more affordable, accessible cure for malaria, which kills more than a million children each year.

OneWorld Health, which announced the grant today (Monday, Dec. 13), will work in partnership with the University of California, Berkeley, and Amyris Biotechnologies. UC Berkeley will conduct research to perfect a microbial factory for the compound artemisinin, currently the most effective treatment for malaria, and Amyris, a new biotech company founded on the breakthroughs in synthetic biology pioneered at UC Berkeley, will develop the process for industrial fermentation and commercialization. OneWorld Health will perform the drug development and regulatory work to demonstrate the bioequivalence of microbially-produced artemisinin derivative to the drug's natural form.

Malaria has become increasingly resistant to front-line medications, but combination drugs containing artemisinin show nearly 100 percent effectiveness after a short three-day regimen. Yet, at a price of $2.40 per adult course for artemisinin combination therapies provided through the World Health Organization, these drugs are still beyond the reach of millions of the world's poorest people. Artemisinin is in short supply, and producing it currently is labor-intensive and relatively expensive.

The partnership will utilize a high-technology solution to bring down the cost of treatment to well under a dollar, a price more affordable for patients in developing countries.

"This is an extraordinary partnership between public and private institutions that combines cutting-edge science with a commitment to affordability and accessibility for those people in need," said Regina Rabinovich, M.D., M.P.H., director of infectious diseases at the Bill & Melinda Gates Foundation. "I hope that UC Berkeley's participation will serve as a model for other academic institutions to apply their scientific knowledge and resources to critical global health problems."

Each year, between 300 and 500 million people, most of them poor, become infected with malaria, and at least 1.5 million die, primarily children in Africa and Asia.

"With UC Berkeley's innovative technology, Amyris' advancement of this new process, and our drug development and regulatory expertise, we'll provide a new, scalable and stable supply of affordable antimalarials for the developing world," said Victoria Hale, Ph.D., founder and CEO of OneWorld Health.

To ensure affordability, UC Berkeley has issued a royalty-free license to both OneWorld Health and Amyris, of Albany, Calif., to develop the technology for malaria treatments. In exchange, Amyris will produce the drugs at cost, and OneWorld Health will perform the detailed non-clinical regulatory work that will be required by United States and other global agencies to allow the low-cost, microbially-based product to be substituted for plant-based product by manufacturers of combination drugs containing artemisinin. The nonprofit nature of this partnership could be a model for attacking neglected diseases in the developing world, said Jay Keasling, Ph.D., professor of chemical engineering at UC Berkeley, who created the genetically engineered microbial drug factories. Keasling also is director of the synthetic biology department at Lawrence Berkeley National Laboratory and a California Institute for Quantitative Biomedical Research (QB3) faculty affiliate.

"This project will use some of the latest advances in molecular biology to engineer a microbial chemical factory and reduce the cost of a much-needed drug tenfold," he said. "In many ways, this project is a dream project: interesting science, high technology, rapid transition from the bench to the bedside, and most important, critical need."

To produce the artemisinin, Keasling and his team have genetically modified microbes. This approach, one of the first triumphs of a field called synthetic biology, also produces a reliably pure compound. While synthetic biology can be used to create any number of useful chemicals called isoprenoids that form the basis for products such as perfumes and flavorings, Keasling has chosen to focus on the creation of much-needed pharmaceuticals, such as artemisinin, for the developing world.

Extraction of artemisinin from the wormwood plant is labor intensive and, in some developing countries, it is produced by a diesel fuel purification process that may retain toxic impurities in the final drug product. UC Berkeley will complete development of the synthetic process and maximize production of artemisinic acid, a precursor to artemisinin. The breakthrough technology that makes all this possible was developed by Keasling and his UC Berkeley team over the past 10 years.

Amyris will develop processes to produce large quantities of microbial artemisinic acid and chemically convert it to artemisinin and other effective medicines. These new processes can be easily scaled to meet the enormous demand for low-cost pharmaceuticals in developing countries.

"We're focusing our groundbreaking technology on producing a known pharmaceutical -- the most effective antimalarial out there -- so that it reaches the people who need it most. This is just the beginning of drug production using synthetic biology," said Jack D. Newman, Ph.D., a founding scientist at Amyris.
-end-
The Institute for OneWorld Health, the first U.S. nonprofit pharmaceutical company, develops new, affordable medicines for infectious diseases that disproportionately affect people in the developing world. OneWorld Health applies its entrepreneurial business model with a staff of experienced pharmaceutical scientists that identifies promising leads and drives development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3) U.S. corporation (http://www.oneworldhealth.org/). Media resources are available at http://www.oneworldhealth.org/media/index.php/.

At UC Berkeley, the Keasling laboratory has pioneered the use of synthetic biology to engineer bacteria to produce useful drugs and to degrade toxic environmental contaminants. Jay Keasling can be reached at 510-642-4862 or keasling@socrates.berkeley.edu. The Keasling lab's Web site is http://www.cchem.berkeley.edu/~jdkgrp/. Video of Keasling, Hale and Newman is available from UC Berkeley Media Relations. (Contact Julie Huang at 510-642-6051 or jch@pa.urel.berkeley.edu). The QB3 Web site is http://www.qb3.org/.

Amyris Biotechnologies, Inc. uses synthetic biology to produce complex natural chemicals important to the pharmaceutical and fine chemical industries. Using engineered microbes and high-throughput gene discovery, Amyris gains access to promising new drugs that have not been developed because of supply limitations. Amyris employs a variety of new biosynthetic pathways engineered in microbes to produce a range of high-value molecules in large scale at low cost. Amyris' Web site is http://www.amyrisbiotech.com/.

University of California - Berkeley

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.